Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer
NCT00091832
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
255
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Cancer
Metastases
Bone Metastases in Subjects With Advanced Breast Cancer
Interventions
BIOLOGICAL:
Denosumab
DRUG:
IV Bisphosphonates
Sponsor
Amgen